Evidence map›Paper›PMID 41323549›Full record

ArticleLancet regional health. Americas2025

Healthcare costs and resource utilization for acute respiratory syncytial virus pediatric hospitalizations in Canada: a population-based study.

Nirma Khatri Vadlamudi, Kyle Gomes, Ethan Chow, Malou Bourdeau, Joanne Embree, Scott A Halperin, Taj Jadavji, Kescha Kazmi, Joanne M Langley, Nicole Le Saux and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lancet regional health. Americas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Nirma Khatri VadlamudiVaccine Evaluation Center, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
Kyle GomesVaccine Evaluation Center, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
Ethan ChowVaccine Evaluation Center, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
Malou BourdeauFaculty of Medicine, McGill University, Montreal, Quebec, Canada.
Joanne EmbreeDepartment of Pediatrics, University of Manitoba, Winnipeg, Canada.
Scott A HalperinCanadian Center for Vaccinology, IWK and Nova Scotia Health, Dalhousie University, Halifax, Nova Scotia, Canada.
Taj JadavjiInfectious Diseases, Department of Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada.
Kescha KazmiDivision of Infectious Diseases, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Joanne M LangleyCanadian Center for Vaccinology, IWK and Nova Scotia Health, Dalhousie University, Halifax, Nova Scotia, Canada.
Nicole Le SauxDivision of Infectious Diseases, Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
Dorothy MooreFaculty of Medicine, McGill University, Montreal, Quebec, Canada.
Shaun K MorrisDivision of Infectious Diseases, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Jeffrey M PernicaDivision of Infectious Diseases, Department of Pediatrics, McMaster's University, Hamilton, Ontario, Canada.
Joan RobinsonDepartment of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
Manish SadaranganiVaccine Evaluation Center, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
Julie A BettingerVaccine Evaluation Center, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
Canadian Immunization Monitoring Program Active (IMPACT) Members

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Respiratory syncytial virus (RSV) is a major cause of bronchiolitis and pneumonia in pediatric populations, especially in infancy. This study aims to assess overall and age-specific incidence of RSV-associated hospitalization and healthcare resource use throughout childhood in Canada. Methods: Data were retrieved from a national administrative dataset, which captured hospitalizations with International Classification of Diseases (ICD) codes, tenth revision from participating Canadian hospitals (Canadian Institute for Health Information, CIHI), and from an active surveillance program in tertiary care pediatric hospitals (the Canadian Immunization Program ACTive, IMPACT). Children aged 0-16 years with RSV in November 2017 through April 2023 were eligible. We estimated overall and age-specific RSV hospitalization incidence, healthcare resource use (length of stay, mechanical ventilation use), and costs by age group (0-5, 6-11, and 12-23 months, and 2-4 years, 5-9 years, 10-16 years). Costs were adjusted to 2022 Canadian dollars (CAD). The population denominator for age-specific RSV incidence estimates was retrieved from Statistics Canada. Findings: An estimated 29,277 RSV hospitalizations occurred, with an average of 5831 cases/year in pre-pandemic years (November 2017-June 2020). Infants aged <6 months old accounted for 13,055 (44.6%) of cases for study duration (November 2017-April 2023). RSV incidence among infants aged <6 months increased from 1250 per 100,000 in November 2017-June 2018 to 2393 per 100,000 in July 2022-April 2023. The average annual cost of RSV was $66,267,950 CAD. Infants <6 months old accounted for 49.0% ($32,471,296 CAD) of annual average RSV healthcare costs. Interpretation: Although RSV occurs throughout childhood, the high RSV hospitalization incidence in infants younger than 6 months of age highlights an urgent need for prevention strategies in this population to alleviate the health burden in this population and economic burden on healthcare systems. Funding: This surveillance activity is conducted as part of the Canadian Immunization Monitoring Program Active (IMPACT), a national surveillance initiative managed by the Canadian Paediatric Society (CPS) and conducted by the IMPACT network of pediatric investigators. Funding for RSV surveillance was provided by the Public Health Agency of Canada; funding for RSV economic burden analyses was provided by Sanofi and AstraZeneca.

Indexed as

Economic burdenHealth servicesInfantObservational studyRespiratory infections

Identifiers

PMID41323549
PMCPMC12664583

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.